The post Is XRP ETF Possible? Top Expert Shuts Down Speculations appeared on BitcoinEthereumNews.com. The endless back-and-forth on whether an XRP ETF would ever matter seems to have finally met a full stop. Nate Geraci, who has built a reputation as one of the most expert ETF watchers, went straight to the point this week: Demand for a spot XRP fund is being badly misread. To him, it feels the same way people shrugged off Bitcoin and Ethereum ETFs at first, only to watch billions pour in once the doors opened. You Might Also Like Geraci’s latest comment lands right at the time as the SEC’s table is overflowing: 92 crypto ETF filings are waiting. Out of those, the familiar Bitcoin and Ethereum get a few more products, but the real action has shifted. Solana has eight filings on record, XRP sits at seven, and the queue keeps growing. You heard it here first… People are severely underestimating investor demand for spot xrp & sol ETFs. Just like they did w/ spot btc & eth ETFs. — Nate Geraci (@NateGeraci) September 1, 2025 These all are not just random startups either. Names like WisdomTree, whose XRP ETF decision was pushed back on Aug. 25, and several heavyweight managers are filing amendments with October deadlines. A calendar for fall on the crypto market now feels like a set of alarms. Was XRP ‘next Bitcoin’ whole time? At the same time, a few signals have already been dropped on the institutional side. Thus, Canary Capital called XRP the only asset, besides Bitcoin, that actually resonates with Wall Street pros. Amplify is testing a different spin altogether, pitching an ETF that generates income from XRP options. Hard to argue, fund managers wouldn’t be filing without at least some expectation of approval. You Might Also Like And Geraci isn’t guessing from the sidelines. He was early on Bitcoin ETFs, and he was… The post Is XRP ETF Possible? Top Expert Shuts Down Speculations appeared on BitcoinEthereumNews.com. The endless back-and-forth on whether an XRP ETF would ever matter seems to have finally met a full stop. Nate Geraci, who has built a reputation as one of the most expert ETF watchers, went straight to the point this week: Demand for a spot XRP fund is being badly misread. To him, it feels the same way people shrugged off Bitcoin and Ethereum ETFs at first, only to watch billions pour in once the doors opened. You Might Also Like Geraci’s latest comment lands right at the time as the SEC’s table is overflowing: 92 crypto ETF filings are waiting. Out of those, the familiar Bitcoin and Ethereum get a few more products, but the real action has shifted. Solana has eight filings on record, XRP sits at seven, and the queue keeps growing. You heard it here first… People are severely underestimating investor demand for spot xrp & sol ETFs. Just like they did w/ spot btc & eth ETFs. — Nate Geraci (@NateGeraci) September 1, 2025 These all are not just random startups either. Names like WisdomTree, whose XRP ETF decision was pushed back on Aug. 25, and several heavyweight managers are filing amendments with October deadlines. A calendar for fall on the crypto market now feels like a set of alarms. Was XRP ‘next Bitcoin’ whole time? At the same time, a few signals have already been dropped on the institutional side. Thus, Canary Capital called XRP the only asset, besides Bitcoin, that actually resonates with Wall Street pros. Amplify is testing a different spin altogether, pitching an ETF that generates income from XRP options. Hard to argue, fund managers wouldn’t be filing without at least some expectation of approval. You Might Also Like And Geraci isn’t guessing from the sidelines. He was early on Bitcoin ETFs, and he was…

Is XRP ETF Possible? Top Expert Shuts Down Speculations

The endless back-and-forth on whether an XRP ETF would ever matter seems to have finally met a full stop. Nate Geraci, who has built a reputation as one of the most expert ETF watchers, went straight to the point this week: Demand for a spot XRP fund is being badly misread.

To him, it feels the same way people shrugged off Bitcoin and Ethereum ETFs at first, only to watch billions pour in once the doors opened.

You Might Also Like

Geraci’s latest comment lands right at the time as the SEC’s table is overflowing: 92 crypto ETF filings are waiting. Out of those, the familiar Bitcoin and Ethereum get a few more products, but the real action has shifted. Solana has eight filings on record, XRP sits at seven, and the queue keeps growing.

These all are not just random startups either. Names like WisdomTree, whose XRP ETF decision was pushed back on Aug. 25, and several heavyweight managers are filing amendments with October deadlines. A calendar for fall on the crypto market now feels like a set of alarms.

Was XRP ‘next Bitcoin’ whole time?

At the same time, a few signals have already been dropped on the institutional side. Thus, Canary Capital called XRP the only asset, besides Bitcoin, that actually resonates with Wall Street pros. Amplify is testing a different spin altogether, pitching an ETF that generates income from XRP options.

Hard to argue, fund managers wouldn’t be filing without at least some expectation of approval.

You Might Also Like

And Geraci isn’t guessing from the sidelines. He was early on Bitcoin ETFs, and he was early on Ethereum too. Both times the market thought small, both times it was wrong. His call on XRP fits the same pattern.

If the SEC finally waves approval through, the speculation will end once and for all.

Source: https://u.today/is-xrp-etf-possible-top-expert-shuts-down-speculations

Market Opportunity
LETSTOP Logo
LETSTOP Price(STOP)
$0.01427
$0.01427$0.01427
-3.12%
USD
LETSTOP (STOP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26